ACE2 and COVID-19: In patients with moderate and severe COVID-19, the inflammatory response is induced by, e.g., the ACE2 pathway, where, due to the binding of the virus to ACE2, this enzyme does not convert angiotensin II to the anti-inflammatory angiotensin 1–7 [17,18,19,20,21].